Financials in GBp. Standardized financial statements.
A compact view of how Fusion Antibodies plc turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £1.97M | £1.14M | £2.90M | £4.80M | £4.17M | £3.90M | £2.18M | £2.69M | £1.91M | £1.48M |
| Revenue Growth? | +73.0% | -60.8% | -39.5% | +15.2% | +6.9% | +78.5% | -18.9% | +40.6% | +29.2% | 0.0% |
| Cost of Revenue? | £1.53M | £1.40M | £2.70M | £3.08M | £2.85M | £2.74M | £1.38M | £1.21M | £952,459 | £618,055 |
| Gross Profit? | £430,000 | -£265,000 | £202,000 | £1.72M | £1.31M | £1.15M | £804,002 | £1.48M | £961,497 | £863,210 |
| Gross Margin? | +21.9% | -23.3% | +7.0% | +35.8% | +31.5% | +29.6% | +36.8% | +55.1% | +50.2% | +58.3% |
| Operating Expenses? | £2.21M | £2.24M | £3.04M | £3.05M | £2.69M | £2.27M | £2.31M | £2.19M | £834,967 | £835,525 |
| Operating Income? | -£1.78M | -£2.29M | -£2.83M | -£1.33M | -£1.38M | -£1.11M | -£1.51M | £62,393 | £126,530 | £27,685 |
| EBITDA? | -£1.62M | -£2.06M | -£2.48M | -£573,000 | -£532,000 | -£431,000 | -£1.06M | -£636,879 | £288,473 | £49,921 |
| Income Before Tax | -£1.78M | -£2.29M | -£2.86M | -£1.33M | -£1.26M | -£1.07M | -£1.50M | -£711,362 | £125,915 | £27,189 |
| Income Tax Expense | £64,000 | -£63,000 | -£263,000 | -£133,000 | £1.64M | -£376,000 | -£235,489 | -£11,421 | £5,961 | -£1.13M |
| Net Income? | -£1.71M | -£2.23M | -£2.60M | -£1.20M | -£2.90M | -£697,000 | -£1.26M | -£699,941 | £119,954 | £1.15M |
| EPS? | £-0.02 | £-0.04 | £-0.10 | £-0.05 | £-0.11 | £-0.03 | £-0.06 | £-0.04 | £0.01 | £0.05 |
| Diluted EPS? | £-0.02 | £-0.04 | £-0.10 | £-0.05 | £-0.11 | £-0.03 | £-0.06 | £-0.04 | £0.01 | £0.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality